Silicon Valley Capital Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Silicon Valley Capital Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-45	Closed	-$22.2K	–	332
2025 Q1	$22.2K	Hold	45	–	–	﹤0.01%	171
2024 Q4	$18.1K	Hold	45	–	–	﹤0.01%	209
2024 Q3	$20.9K	Hold	45	–	–	﹤0.01%	186
2024 Q2	$21.1K	Hold	45	–	–	﹤0.01%	187
2024 Q1	$18.8K	Hold	45	–	–	﹤0.01%	181
2023 Q4	$18.3K	Hold	45	–	–	﹤0.01%	194
2023 Q3	$15.6K	Hold	45	–	–	﹤0.01%	158
2023 Q2	$15.8K	Buy	+45	New	+$15.2K	﹤0.01%	154

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Silicon Valley Capital Partners's VRTX Position: Q2 2025 in Review

Silicon Valley Capital Partners sold out of Vertex Pharmaceuticals (VRTX) in Q2 2025, closing a stake of 45 shares — an estimated $22.2K sold.

Silicon Valley Capital Partners first reported a position in VRTX in Q2 2023 and held it in 8 quarters. The position peaked at $22.2K in Q1 2025. 1,563 funds tracked by Wall St. Rank hold VRTX as of Q2 2025.

Silicon Valley Capital Partners reported no remaining Vertex Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Silicon Valley Capital Partners sold 45 Vertex Pharmaceuticals shares in Q2 2025, an estimated $22.2K.
Silicon Valley Capital Partners first reported a position in Vertex Pharmaceuticals in Q2 2023 and held it in 8 quarters.
Silicon Valley Capital Partners's Vertex Pharmaceuticals position peaked at $22.2K in Q1 2025.
1,563 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2025.

Based on Silicon Valley Capital Partners's 13F filing for Q2 2025, filed 11 Sep 2025.